Researchers develop gene classifier to predict DCIS risk of cancer progression

A team of researchers mapping a molecular atlas for ductal carcinoma in situ (DCIS) has made a major advance toward distinguishing whether the early pre-cancers in the breast will develop into invasive cancers or remain stable.

Tempus Donates Over 3,000 Cancer Patient Profiles to Fuel National Cancer Institute Research

What You Should Know: – Tempus, a leader in artificial intelligence and precision medicine, announced a groundbreaking data contribution to the National Cancer Institute (NCI)

March 15, 2024

Is a contrarian leader good for the FDA?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we have

December 20, 2024

Those Studies Backing Vagus Nerve Stimulation for RA? Umm…

Rheumatoid arthritis (RA) patients got no benefit from vagus nerve stimulation (VNS) in a sham-controlled trial, in sharp contrast to previous open-label studies, researchers said.

July 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.